Contents

Highlights of This Issue 6953

SPECIAL FEATURES

CCR Translations

6955 MAGE: The Spell Is Broken
Katayoun Rezvani
See article p. 7058

CCR Drug Updates

6958 Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson and Charles G. Drake

Molecular Pathways

6963 Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells
Nicola Giuliani and Irma Airoldi

Perspective

6971 DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies
Graham A. Colditz and John Crowley

Reviews

6973 DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Shadid Jalal, Jennifer N. Earley, and John J. Turchi

6985 Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier, Laila-Aicha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

HUMAN CANCER BIOLOGY

Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
Trisha R. Sippel, Jason White, Kamalika Nag, Vaidam Tsvankin, Marci Kaassen, B.K. Kleinschmidt-DeMasters, and Allen Waziri

6992

7003

7015

7024

7035

Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome

Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma
David Z. Chang, Ying Ma, Baean Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yong-jun Liu, Craig D. Logsdon, and Patrick Hwu

Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis

Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu
CANCER THERAPY: PRECLINICAL

7047 Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Yuhuan Li, Li-Xin Wang, Puiyai Pang, Zhihua Cui, Sandra Aung, Daniel Hable, Bernard A. Fox, Walter J. Urba, and Hong-Ming Ha

7058 Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Conrad R. Cruz, Ulrike Gerdemann, Ann M.leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzo, Terzah M. Horton, Andrea Shrehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, and Catherine M. Bollard
See commentary p. 6955

7067 Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

7080 Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

IMAGING, DIAGNOSIS, PROGNOSIS

7139 Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival
Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutter, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

7148 A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendrogial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent, Lonneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Larisa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idibaih, Marc Sanson, Peter A.E. Sillevis Smitt, and Pip J. French

CANCER THERAPY: CLINICAL

7156 Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, and Jaap Verweij

7164 A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Malsba Mohtesham, Kwong-Yuk Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jiacquin Jones, Therese Ferrara, Christopher B. Heery, Philip M. Arel, Seth M. Steinberg, Mary Pazdur, Myra Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlimo, and James L. Gulley
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohsuke Edamura, Ken-ichi Tabata, Chengzheng Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.